FGAM
VERV

Financial Gravity Asset Management’s Verve Therapeutics VERV Stock Holding History

Financial Gravity Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$111 – 2404
2024
Q1 		$111 Buy
10
+8
+400% +$106 ﹤0.01% 1723
2023
Q4 		$15 Buy
2
+1
+100% +$12 ﹤0.01% 1453
2023
Q3 		$6 Sell
1
-18
-95% -$290 ﹤0.01% 1187
2023
Q2 		$61 Buy
+19
New +$316 ﹤0.01% 1377

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Financial Gravity Asset Management's VERV Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 10 shares — an estimated $111 sold.

Financial Gravity Asset Management first reported a position in VERV in Q2 2023 and held it in 4 quarters. The position peaked at $111 in Q1 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 10 Verve Therapeutics shares in Q2 2024, an estimated $111.
  • Financial Gravity Asset Management first reported a position in Verve Therapeutics in Q2 2023 and held it in 4 quarters.
  • Financial Gravity Asset Management's Verve Therapeutics position peaked at $111 in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.